Literature DB >> 26891147

Modeling Chemotherapy Resistant Leukemia In Vitro.

William L Slone1, Blake S Moses1, Rebecca Evans1, Debbie Piktel1, Karen H Martin2, William Petros1, Michael Craig1, Laura F Gibson3.   

Abstract

It is well established that the bone marrow microenvironment provides a unique site of sanctuary for hematopoietic diseases that both initiate and progress in this site. The model presented in the current report utilizes human primary bone marrow stromal cells and osteoblasts as two representative cell types from the marrow niche that influence tumor cell phenotype. The in vitro co-culture conditions described for human leukemic cells with these primary niche components support the generation of a chemoresistant subpopulation of tumor cells that can be efficiently recovered from culture for analysis by diverse techniques. A strict feeding schedule to prevent nutrient fluxes followed by gel type 10 cross-linked dextran (G10) particles recovery of the population of tumor cells that have migrated beneath the adherent bone marrow stromal cells (BMSC) or osteoblasts (OB) generating a "phase dim" (PD) population of tumor cells, provides a consistent source of purified therapy resistant leukemic cells. This clinically relevant population of tumor cells can be evaluated by standard methods to investigate apoptotic, metabolic, and cell cycle regulatory pathways as well as providing a more rigorous target in which to test novel therapeutic strategies prior to pre-clinical investigations targeted at minimal residual disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26891147      PMCID: PMC4781739          DOI: 10.3791/53645

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

1.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

2.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.

Authors:  E Coustan-Smith; J Sancho; M L Hancock; J M Boyett; F G Behm; S C Raimondi; J T Sandlund; G K Rivera; J E Rubnitz; R C Ribeiro; C H Pui; D Campana
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

3.  Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.

Authors:  Yordanos Tesfai; Jette Ford; Kim W Carter; Martin J Firth; Rebecca A O'Leary; Nicholas G Gottardo; Catherine Cole; Ursula R Kees
Journal:  Leuk Res       Date:  2011-09-01       Impact factor: 3.156

4.  VE-cadherin Regulates Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Sensitivity to Apoptosis.

Authors:  Heather O'Leary; Stephen M Akers; Debra Piktel; Cheryl Walton; James E Fortney; Karen H Martin; Michael Craig; James Coad; Laura F Gibson
Journal:  Cancer Microenviron       Date:  2010-03-02

5.  MMP-2 is required for bone marrow stromal cell support of pro-B-cell chemotaxis.

Authors:  Suzanne D Clutter; James Fortney; Laura F Gibson
Journal:  Exp Hematol       Date:  2005-10       Impact factor: 3.084

6.  VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli.

Authors:  L Wang; L Chen; J Benincosa; J Fortney; L F Gibson
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

7.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

8.  Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells.

Authors:  A Manabe; K G Murti; E Coustan-Smith; M Kumagai; F G Behm; S C Raimondi; D Campana
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

9.  Depletion of accessory cells by adherence to Sephadex G-10.

Authors:  K S Hathcock
Journal:  Curr Protoc Immunol       Date:  2001-05

Review 10.  Contribution of bone microenvironment to leukemogenesis and leukemia progression.

Authors:  F Ayala; R Dewar; M Kieran; R Kalluri
Journal:  Leukemia       Date:  2009-09-03       Impact factor: 11.528

View more
  8 in total

1.  Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia.

Authors:  Blake S Moses; Rebecca Evans; William L Slone; Debbie Piktel; Ivan Martinez; Michael D Craig; Laura F Gibson
Journal:  Mol Cancer Res       Date:  2016-06-29       Impact factor: 5.852

2.  Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia.

Authors:  Rajesh R Nair; Werner J Geldenhuys; Debbie Piktel; Prabodh Sadana; Laura F Gibson
Journal:  Bioorg Med Chem Lett       Date:  2018-03-23       Impact factor: 2.823

3.  The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.

Authors:  Werner J Geldenhuys; Rajesh R Nair; Debbie Piktel; Karen H Martin; Laura F Gibson
Journal:  J Pharmacol Exp Ther       Date:  2019-04-22       Impact factor: 4.030

4.  Pitavastatin Is Anti-Leukemic in a Bone Marrow Microenvironment Model of B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Debbie Piktel; Rajesh R Nair; Stephanie L Rellick; Werner J Geldenhuys; Karen H Martin; Michael D Craig; Laura F Gibson
Journal:  Cancers (Basel)       Date:  2022-05-28       Impact factor: 6.575

5.  Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment.

Authors:  Rajesh R Nair; Debbie Piktel; Quincy A Hathaway; Stephanie L Rellick; Patrick Thomas; Pushkar Saralkar; Karen H Martin; Werner J Geldenhuys; John M Hollander; Laura F Gibson
Journal:  Pharm Res       Date:  2020-01-27       Impact factor: 4.200

6.  BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.

Authors:  William L Slone; Blake S Moses; Ian Hare; Rebecca Evans; Debbie Piktel; Laura F Gibson
Journal:  Oncotarget       Date:  2016-04-26

7.  CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).

Authors:  Yongfang Jiang; Ping Xu; Dandan Yao; Xi Chen; Haibin Dai
Journal:  Med Sci Monit       Date:  2017-04-09

8.  Co-culture model of B-cell acute lymphoblastic leukemia recapitulates a transcription signature of chemotherapy-refractory minimal residual disease.

Authors:  Stephanie L Rellick; Gangqing Hu; Debra Piktel; Karen H Martin; Werner J Geldenhuys; Rajesh R Nair; Laura F Gibson
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.